Not available
Quote | Mesabi Trust (NYSE:MSB)
Last: | $17.54 |
---|---|
Change Percent: | 0.06% |
Open: | $17.43 |
Close: | $17.54 |
High: | $17.62 |
Low: | $17.22 |
Volume: | 12,153 |
Last Trade Date Time: | 07/02/2024 03:00:00 am |
News | Mesabi Trust (NYSE:MSB)
NEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today confirmed that it will file its Biologics License Application (BLA) for approval of Ryoncil ® (remestemcel-L) in the treat...
2024-06-16 08:00:00 ET Close on the heels of fellow homebuilder Lennar's ( LEN ) results, KB Home ( KBH ) is set to report its financial figures after the market closes on Tuesday. Analysts are expecting Y/Y declines in both revenue and earnings. ... Read the full article...
Message Board Posts | Mesabi Trust (NYSE:MSB)
Subject | By | Source | When |
---|---|---|---|
Northshore Mining on Iron Range open again after | Enterprising Investor | investorshub | 04/26/2023 12:43:24 PM |
ValueWorks LLC beneficially owns 806,437 shares (4/24/23) | Enterprising Investor | investorshub | 04/25/2023 9:28:46 AM |
Horizon Kinetics Asset Management LLC beneficially owns 2,684,726 | Enterprising Investor | investorshub | 04/25/2023 9:26:29 AM |
Form 10-K (4/24/23) | Enterprising Investor | investorshub | 04/25/2023 9:24:02 AM |
Mesabi Trust Press Release (4/14/23) | Enterprising Investor | investorshub | 04/21/2023 12:29:27 AM |
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today confirmed that it will file its Biologics License Application (BLA) for approval of Ryoncil ® (remestemcel-L) in the treat...
Orbital Infrastructure Group Inc. (OIGBQ) is expected to report for Q1 2024 OFS Credit Company Inc. (OCCI) is expected to report for Q2 2024 KBC Groupe NV ADR (KBCSY) is expected to report for Q1 2024 Daikin Industries Ltd ADR (DKILY) is expected to report $0.11 for Q4 2024 Invita...
NEW YORK, June 02, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), Chief Executive Silviu Itescu provided a corporate update at the Bell Potter Emerging Leaders Conference. Dr. Itescu reiterated that the Company expects to file this quarter the Biologics License Applicati...